Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Tolkachjov SN et al. | Frontal fibrosing alopecia among men: AÂ clinicopathologic study of 7 cases. | 2017 | J. Am. Acad. Dermatol. | pmid:28716436 |
Montenovo MI et al. | Superior Patient and Graft Survival in Adult Liver Transplant with Rabbit Antithymocyte Globulin Induction: Experience with 595 Patients. | 2017 | Exp Clin Transplant | pmid:27309029 |
Solmaz S et al. | Tacrolimus-Induced Diabetic Ketoacidosis After Allogeneic Bone Marrow Transplant. | 2017 | Exp Clin Transplant | pmid:26643544 |
Das B et al. | Alemtuzumab (Campath-1H) therapy for refractory rejections in pediatric heart transplant recipients. | 2017 | Pediatr Transplant | pmid:27862703 |
Tamashiro EY et al. | Influence of CYP3A4 and CYP3A5 polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients. | 2017 | Drug Metab Pers Ther | pmid:28593920 |
Charman C | A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal - comment. | 2017 | Br. J. Dermatol. | pmid:28858382 |
Gerlach UA et al. | Intragraft and Systemic Immune Parameters Discriminating Between Rejection and Long-Term Graft Function in a Preclinical Model of Intestinal Transplantation. | 2017 | Transplantation | pmid:27607529 |
Ramirez R et al. | Posterior Reversible Encephalopathy Syndrome After Orthotopic Heart Transplantation: A Case Report. | 2017 | Am J Case Rep | pmid:28465499 |
Chen B et al. | Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorder. | 2017 | Sci Rep | pmid:28400553 |
Song K et al. | Engineering of the LysR family transcriptional regulator FkbR1 and its target gene to improve ascomycin production. | 2017 | Appl. Microbiol. Biotechnol. | pmid:28349163 |
Wan T et al. | Effects of nanoparticles with hydrotropic nicotinamide on tacrolimus: permeability through psoriatic skin and antipsoriatic and antiproliferative activities. | 2017 | Int J Nanomedicine | pmid:28260894 |
Ferjani H et al. | Beneficial effects of mycophenolate mofetil on cardiotoxicity induced by tacrolimus in wistar rats. | 2017 | Exp. Biol. Med. (Maywood) | pmid:26582055 |
Moes AD et al. | Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial. | 2017 | Am. J. Kidney Dis. | pmid:28259499 |
Tremblay S et al. | A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study. | 2017 | Am. J. Transplant. | pmid:27340950 |
Qin HZ et al. | Evaluating tacrolimus treatment in idiopathic membranous nephropathy in a cohort of 408 patients. | 2017 | BMC Nephrol | pmid:28056860 |
Terakura S et al. | Exploratory research for optimal GvHD prophylaxis after single unit CBT in adults: short-term methotrexate reduced the incidence of severe GvHD more than mycophenolate mofetil. | 2017 | Bone Marrow Transplant. | pmid:27941766 |
Kannegieter NM et al. | Pharmacodynamic Monitoring of Tacrolimus-Based Immunosuppression in CD14+ Monocytes After Kidney Transplantation. | 2017 | Ther Drug Monit | pmid:28640063 |
Wojciechowski D et al. | Mycophenolate Mofetil Withdrawal With Conversion to Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients. | 2017 | Transplant. Proc. | pmid:28923623 |
Nanmoku K et al. | Effective and Safe Reduction of Conventional Immunosuppressants Using Everolimus in Maintenance Kidney Transplant Recipients. | 2017 | Transplant. Proc. | pmid:28923615 |
Gatault P et al. | Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study. | 2017 | Am. J. Transplant. | pmid:27862923 |